Home  |  Contact

UniProtKB/Swiss-Prot Q86YL7: Variant p.Ala147Gly

Podoplanin
Gene: PDPN
Chromosomal location: 1p36.21
Variant information

Variant position:  147
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Polymorphism
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Alanine (A) to Glycine (G) at position 147 (A147G, p.Ala147Gly).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from small size and hydrophobic (A) to glycine (G)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  147
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  162
The length of the canonical sequence.

Location on the sequence:   STVTLVGIIVGVLLAIGFIG  A IIVVVMRKMSGRYSP
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         STVTLVGIIVGVLLAIGFIGAIIVVVMRKMSGRYSP

                              ATVTLVGIIVGVLLAIGFIGGIIIVVARKMSGRYSP

Mouse                         PVVTLVGIIVGVLLAIGFVGGIFIVVMKKISGRFSP

Rat                           AVVTLVGIIIGVLLAIGFIGGIIIVVMRKISGRFSP

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 23 – 162 Podoplanin
Transmembrane 132 – 152 Helical
Alternative sequence 162 – 162 P -> EVNSLHPCDRQMKAIVSRTQIFELIEISDISWVWWLVPVVSAAGQLQTSLGNIVRPCLKKIISGTMVMFQSSLLGPLECSGSHLESQCFERLRRQEVHLCPGI. In isoform 2.
Mutagenesis 137 – 137 Missing. Prevents self-assembly and association to lipid rafts. Reduces the recruitment to invadopodium. Disrupts assembly into adhesion rings. Fails invadopodia-mediated ECM degradation.
Mutagenesis 159 – 159 R -> N. Highly decreases interaction with the EZR and MSN. Induces an intermediate phenotype between epithelial and mesenchymal. Does not affect localization at cell surface protrusions. Induces reorganization of the actin cytoskeleton oncomitantly with the induced morphological changes. Increases cell migration individually. Increases invasiveness. Enhances RHOA activity. Colocalizes at cell-surface protrusions with RHOA and RAC1.


Literature citations

Evidence against a role of mouse, rat, and two cloned human T1alpha isoforms as a water channel or a regulator of aquaporin-type water channels.
Ma T.; Yang B.; Matthay M.A.; Verkman A.S.;
Am. J. Respir. Cell Mol. Biol. 19:143-149(1998)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2); FUNCTION; VARIANT GLY-147;

Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium.
Zimmer G.; Oeffner F.; von Messling V.; Tschernig T.; Groene H.-J.; Klenk H.-D.; Herrler G.;
Biochem. J. 341:277-284(1999)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); TISSUE SPECIFICITY; GLYCOSYLATION; VARIANT GLY-147;

Submission
Kato Y.; Fujita N.; Tsuruo T.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANT GLY-147;

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3); VARIANT GLY-147;

Complete sequencing and characterization of 21,243 full-length human cDNAs.
Ota T.; Suzuki Y.; Nishikawa T.; Otsuki T.; Sugiyama T.; Irie R.; Wakamatsu A.; Hayashi K.; Sato H.; Nagai K.; Kimura K.; Makita H.; Sekine M.; Obayashi M.; Nishi T.; Shibahara T.; Tanaka T.; Ishii S.; Yamamoto J.; Saito K.; Kawai Y.; Isono Y.; Nakamura Y.; Nagahari K.; Murakami K.; Yasuda T.; Iwayanagi T.; Wagatsuma M.; Shiratori A.; Sudo H.; Hosoiri T.; Kaku Y.; Kodaira H.; Kondo H.; Sugawara M.; Takahashi M.; Kanda K.; Yokoi T.; Furuya T.; Kikkawa E.; Omura Y.; Abe K.; Kamihara K.; Katsuta N.; Sato K.; Tanikawa M.; Yamazaki M.; Ninomiya K.; Ishibashi T.; Yamashita H.; Murakawa K.; Fujimori K.; Tanai H.; Kimata M.; Watanabe M.; Hiraoka S.; Chiba Y.; Ishida S.; Ono Y.; Takiguchi S.; Watanabe S.; Yosida M.; Hotuta T.; Kusano J.; Kanehori K.; Takahashi-Fujii A.; Hara H.; Tanase T.-O.; Nomura Y.; Togiya S.; Komai F.; Hara R.; Takeuchi K.; Arita M.; Imose N.; Musashino K.; Yuuki H.; Oshima A.; Sasaki N.; Aotsuka S.; Yoshikawa Y.; Matsunawa H.; Ichihara T.; Shiohata N.; Sano S.; Moriya S.; Momiyama H.; Satoh N.; Takami S.; Terashima Y.; Suzuki O.; Nakagawa S.; Senoh A.; Mizoguchi H.; Goto Y.; Shimizu F.; Wakebe H.; Hishigaki H.; Watanabe T.; Sugiyama A.; Takemoto M.; Kawakami B.; Yamazaki M.; Watanabe K.; Kumagai A.; Itakura S.; Fukuzumi Y.; Fujimori Y.; Komiyama M.; Tashiro H.; Tanigami A.; Fujiwara T.; Ono T.; Yamada K.; Fujii Y.; Ozaki K.; Hirao M.; Ohmori Y.; Kawabata A.; Hikiji T.; Kobatake N.; Inagaki H.; Ikema Y.; Okamoto S.; Okitani R.; Kawakami T.; Noguchi S.; Itoh T.; Shigeta K.; Senba T.; Matsumura K.; Nakajima Y.; Mizuno T.; Morinaga M.; Sasaki M.; Togashi T.; Oyama M.; Hata H.; Watanabe M.; Komatsu T.; Mizushima-Sugano J.; Satoh T.; Shirai Y.; Takahashi Y.; Nakagawa K.; Okumura K.; Nagase T.; Nomura N.; Kikuchi H.; Masuho Y.; Yamashita R.; Nakai K.; Yada T.; Nakamura Y.; Ohara O.; Isogai T.; Sugano S.;
Nat. Genet. 36:40-45(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 10-162 (ISOFORM 3); VARIANT GLY-147;

Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries.
Otsuki T.; Ota T.; Nishikawa T.; Hayashi K.; Suzuki Y.; Yamamoto J.; Wakamatsu A.; Kimura K.; Sakamoto K.; Hatano N.; Kawai Y.; Ishii S.; Saito K.; Kojima S.; Sugiyama T.; Ono T.; Okano K.; Yoshikawa Y.; Aotsuka S.; Sasaki N.; Hattori A.; Okumura K.; Nagai K.; Sugano S.; Isogai T.;
DNA Res. 12:117-126(2005)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 10-162 (ISOFORM 4); VARIANT GLY-147;

Molecular cloning and characterization of human podoplanin, a small mucin-type glycoprotein of glomerular podocytes.
Kowalski H.; Kalt R.; Auer H.; Dontscho K.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 16-162 (ISOFORM 3); VARIANT GLY-147;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.